Hi there, Thank you for subscribing to MarketBeat Daily Ratings. We're excited to have you onboard! Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. Please take a moment to confirm your subscription by clicking the link below. You may not receive your daily ratings newsletter without confirming your subscription. Click Here to Confirm Your Subscription to MarketBeat Daily Ratings Thank you again for subscribing. We look forward to being an important part of your investing journey.
Matthew Paulson
Founder and CEO, MarketBeat.
Confirm Your Subscription to MarketBeat Daily Ratings Here
Further Reading from MarketBeat 3 Under-the-Radar Biotechs Under $5 That Could Soar 200%Written by Chris Markoch. Published 9/9/2025. 
Key Points - Hoth Therapeutics is advancing mRNA-based therapies for cancer and obesity, with analyst targets implying over 150% upside.
- Silo Pharma combines pre-clinical psychedelic therapies with an obesity drug collaboration and a unique crypto treasury strategy.
- Anixa Biosciences develops cancer immunotherapies in partnership with leading institutions, with nearly 200% analyst upside potential.
Investing in biotechnology stocks often appeals to speculative investors. Many biotech firms are in clinical or pre-clinical stages; they're not yet profitable, and some are pre-revenue, so any payoff could be years away. Many of these companies also fall into the penny stock category (trading under $5 per share), which attracts traders chasing technical signals for quick gains. On July 4th, Trump signed the "One Big Beautiful Bill," adding $3.4 trillion to the national debt — and pushing America's debt-to-GDP ratio to 175%.
Top investors are warning of an epic bubble bursting soon. A free guide reveals how to shield your 401(k), savings, and portfolio before the collapse. Claim your FREE Big Beautiful Bubble Survival Guide now However, patient investors with conviction may find that small-cap biotech stocks offer the chance to build positions with the potential for outsized long-term returns. Below are three under-the-radar biotech stocks trading under $5, each with significant upside potential for those willing to wait. Hoth: Pre-Clinical Cancer Research with Big Market Potential Hoth Therapeutics Inc. (NASDAQ: HOTH) leads this list, with shares up 98% in 2025. Yet at roughly $1.50 per share, HOTH remains about 35% below its January 12-month high. With multiple pre-clinical assets—including an obesity drug candidate—Hoth offers speculative investors exposure to two high-demand markets: oncology and weight-loss treatments. Investors are particularly bullish on the pre-clinical oncology candidate HT-KIT, which leverages mRNA technology to target gastrointestinal stromal tumors (GIST), systemic mastocytosis, and certain leukemias. In vitro studies show HT-KIT achieves over 80% knockdown of KIT expression, the key oncogenic driver in several aggressive cancers. Only two of Hoth's six pipeline candidates are in active clinical trials, leaving it in a pre-revenue phase. However, enthusiasm centers on HT-VA, its obesity treatment candidate, which Hoth exclusively licensed from the U.S. Department of Veterans Affairs. Given the expanding obesity market, analysts assign HOTH a consensus price target of $4—about 150% above current levels. Silo Pharma: Psychedelics, Obesity Treatment, and a Crypto Twist Silo Pharma Inc. (NASDAQ: SILO) has fallen 29% in 2025 but climbed over 7% in the past three months, driven by a non-binding letter of intent to form a 50/50 joint venture with Hoth Therapeutics to develop HT-VA. If finalized, the partnership would give Silo exposure to a global obesity market projected to exceed $100 billion. That represents a pivot from Silo's core focus—developing "novel formulations of traditional and psychedelic therapeutics." Silo's pre-clinical pipeline includes four candidates, such as SP-26 for fibromyalgia and SPU-16 for multiple sclerosis. Speculative investors may also be drawn to Silo's recent cryptocurrency treasury strategy. The company plans to invest in Bitcoin, Ethereum, and Solana, using staking to generate yield while prioritizing capital preservation. Anixa: Micro-Cap Cancer Play with Major Partnerships Anixa Biosciences (NASDAQ: ANIX) concentrates on oncology and is somewhat further along in its clinical journey. Two of Anixa's five pipeline candidates have reached Phase 1 trials. One is a CAR-T immunotherapy for ovarian cancer, activating T cells to attack malignant cells. The other is a vaccine-based therapy designed to generate tumor-specific antigens. The bullish case is bolstered by partnerships with institutions such as the Moffitt Cancer Center, the Cleveland Clinic, and the U.S. Department of Defense. Although analyst coverage is limited, three analysts set a consensus price target of $10—implying roughly 197% upside. These three under-the-radar small-cap biotechs, trading under $5, illustrate the high-risk, high-reward nature of early-stage biotech investing. Patient investors with a tolerance for volatility can gain exposure to oncology, obesity, and novel therapies at potentially attractive entry points.
| 
